{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:55:34Z","timestamp":1709686534701},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00115-021-01090-4","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T11:02:28Z","timestamp":1617102148000},"page":"334-348","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapie antik\u00f6rpervermittelter Enzephalomyelitiden"],"prefix":"10.1007","volume":"92","author":[{"given":"Ilya","family":"Ayzenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"1090_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3389\/fneur.2020.00932","volume":"11","author":"T Akaishi","year":"2020","unstructured":"Akaishi\u00a0T, Takeshita\u00a0T, Himori\u00a0N et\u00a0al (2020) Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neurol 11:932. https:\/\/doi.org\/10.3389\/fneur.2020.00932","journal-title":"Front Neurol"},{"key":"1090_CR2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"I Ayzenberg","year":"2013","unstructured":"Ayzenberg\u00a0I, Kleiter\u00a0I, Schroder\u00a0A et al (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70:394\u2013397","journal-title":"JAMA Neurol"},{"key":"1090_CR3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00415-015-7991-1","volume":"263","author":"I Ayzenberg","year":"2016","unstructured":"Ayzenberg\u00a0I, Schollhammer\u00a0J, Hoepner\u00a0R et\u00a0al (2016) Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a\u00a0multicenter retrospective study. J\u00a0Neurol 263:575\u2013582","journal-title":"J Neurol"},{"key":"1090_CR4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2017","unstructured":"Bonnan\u00a0M, Valentino\u00a0R, Debeugny\u00a0S et\u00a0al (2017) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J\u00a0Neurol Neurosurg Psychiatry 89:346\u2013351","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1090_CR5","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","volume":"95","author":"JJ Chen","year":"2020","unstructured":"Chen\u00a0JJ, Flanagan\u00a0EP, Bhatti\u00a0MT et al (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95:e111\u2013e120","journal-title":"Neurology"},{"key":"1090_CR6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","volume":"16","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo\u00a0A, Sep\u00falveda\u00a0M, Rollot\u00a0F et al (2019) Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J\u00a0Neuroinflammation 16:134","journal-title":"J Neuroinflammation"},{"key":"1090_CR7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi\u00a0C, Matiello\u00a0M, Lucchinetti\u00a0CF et\u00a0al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659\u2013666","journal-title":"Neurology"},{"key":"1090_CR8","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree\u00a0BAC, Bennett\u00a0JL, Kim\u00a0HJ et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394:1352\u20131363","journal-title":"Lancet"},{"key":"1090_CR9","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato\u00a0V, Evoli\u00a0A, Iorio\u00a0R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73:1342\u20131348","journal-title":"JAMA Neurol"},{"key":"1090_CR10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jneuroim.2018.04.016","volume":"321","author":"D Dubey","year":"2018","unstructured":"Dubey\u00a0D, Hinson\u00a0SR, Jolliffe\u00a0EA et\u00a0al (2018) Autoimmune GFAP astrocytopathy: prospective evaluation of 90\u00a0patients in 1\u00a0year. J\u00a0Neuroimmunol 321:157\u2013163","journal-title":"J Neuroimmunol"},{"key":"1090_CR11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14728214.2020.1803828","volume":"25","author":"A Duchow","year":"2020","unstructured":"Duchow\u00a0A, Chien\u00a0C, Paul\u00a0F et\u00a0al (2020) Emerging drugs for the treatment of neuromyelitis optica. Expert Opin Emerg Drugs 25:285\u2013297","journal-title":"Expert Opin Emerg Drugs"},{"key":"1090_CR12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","volume":"87","author":"P Durozard","year":"2020","unstructured":"Durozard\u00a0P, Rico\u00a0A, Boutiere\u00a0C et al (2020) Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin\u20114 antibody diseases. Ann Neurol 87:256\u2013266","journal-title":"Ann Neurol"},{"key":"1090_CR13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone\u00a0L, Kitley\u00a0J, Luppe\u00a0S et al (2014) Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin\u20114 antibody-positive neuromyelitis optica spectrum disorder patients: a\u00a0multicentre retrospective observational study from the UK. Mult Scler 20:1533\u20131540","journal-title":"Mult Scler"},{"key":"1090_CR14","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","volume":"73","author":"B Fang","year":"2016","unstructured":"Fang\u00a0B, Mckeon\u00a0A, Hinson\u00a0SR et\u00a0al (2016) Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 73:1297\u20131307","journal-title":"JAMA Neurol."},{"key":"1090_CR15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","volume":"81","author":"EP Flanagan","year":"2017","unstructured":"Flanagan\u00a0EP, Hinson\u00a0SR, Lennon\u00a0VA et\u00a0al (2017) Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 81:298\u2013309","journal-title":"Ann Neurol"},{"key":"1090_CR16","doi-asserted-by":"crossref","first-page":"175628641876169","DOI":"10.1177\/1756286418761697","volume":"11","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber\u00a0TG, Cimbora\u00a0DM, Ratchford\u00a0JN et al (2018) B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 11:1756286418761697","journal-title":"Ther Adv Neurol Disord"},{"key":"1090_CR17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","volume":"32","author":"K Fujihara","year":"2019","unstructured":"Fujihara\u00a0K (2019) Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 32:385\u2013394","journal-title":"Curr Opin Neurol"},{"key":"1090_CR18","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","volume":"7","author":"K Fujihara","year":"2020","unstructured":"Fujihara\u00a0K, Bennett\u00a0JL, De Seze\u00a0J et al (2020) Interleukin\u20116 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7:e841","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1090_CR19","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1212\/NXI.0000000000000363","volume":"4","author":"A Gahlen","year":"2017","unstructured":"Gahlen\u00a0A, Trampe\u00a0A\u2011K, Haupeltshofer\u00a0S et al (2017) Aquaporin\u20114 antibodies in patients treated with natalizumab for suspected MS. Neurol Neuroimmunol Neuroinflamm 4:e363","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1090_CR20","unstructured":"Hemmer B (2020) Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis Optica Spektrum und MOG-IgG-assoziierte Erkrankungen, S2k-Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. http:\/\/www.dgn.org\/leitlinien. Zugegriffen: 13.\u00a0Nov. 2020"},{"key":"1090_CR21","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00115-017-0439-3","volume":"88","author":"T Henze","year":"2017","unstructured":"Henze\u00a0T, Feneberg\u00a0W, Flachenecker\u00a0P et al (2017) Neues zur symptomatischen MS-Therapie: Teil\u00a02 \u2013 Gangst\u00f6rung und Spastik. Nervenarzt 88:1428\u20131434","journal-title":"Nervenarzt"},{"key":"1090_CR22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard\u00a0JF Jr, Nowak\u00a0RJ, Wolfe\u00a0GI et al (2020) Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a\u00a0phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol 77:582\u2013592","journal-title":"JAMA Neurol"},{"key":"1090_CR23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","volume":"88","author":"J-W Hyun","year":"2017","unstructured":"Hyun\u00a0J\u2011W, Woodhall\u00a0MR, Kim\u00a0S\u2011H et al (2017) Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J\u00a0Neurol Neurosurg Psychiatry 88:811\u2013817","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1090_CR24","series-title":"Nervenarzt","first-page":"1388","volume-title":"MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antik\u00f6rpertestung","author":"S Jarius","year":"2018","unstructured":"Jarius\u00a0S, Paul\u00a0F, Aktas\u00a0O, Asgari\u00a0N, Dale\u00a0RC, Seze\u00a0J de et al (2018) MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antik\u00f6rpertestung. Nervenarzt 89:1388\u20131399"},{"key":"1090_CR25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius\u00a0S, Ruprecht\u00a0K, Kleiter\u00a0I et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50\u00a0patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J\u00a0Neuroinflammation 13:280","journal-title":"J Neuroinflammation"},{"key":"1090_CR26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","volume":"89","author":"S Jarius","year":"2018","unstructured":"Jarius\u00a0S, Paul\u00a0F, Aktas\u00a0O, Asgari\u00a0N, Dale\u00a0RC, Seze\u00a0J de et al (2018) MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antik\u00f6rpertestung.  Nervenarzt 89:1388\u20131399","journal-title":"Nervenarzt"},{"key":"1090_CR27","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk\u00a0M, Messina\u00a0S, Woodhall\u00a0MR et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a\u00a0UK study. Brain 140:3128\u20133138","journal-title":"Brain"},{"key":"1090_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jca.21215","volume":"27","author":"BO Khatri","year":"2012","unstructured":"Khatri\u00a0BO, Kramer\u00a0J, Dukic\u00a0M et al (2012) Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J\u00a0Clin Apher 27:183\u2013192","journal-title":"J Clin Apher"},{"key":"1090_CR29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim\u00a0SH, Huh\u00a0SY, Lee\u00a0SJ et al (2013) A 5\u2011year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70:1110\u20131117","journal-title":"JAMA Neurol"},{"key":"1090_CR30","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","volume":"5","author":"I Kleiter","year":"2018","unstructured":"Kleiter\u00a0I, Gahlen\u00a0A, Borisow\u00a0N et\u00a0al (2018) Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 5:e504","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1090_CR31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter\u00a0I, Gahlen\u00a0A, Borisow\u00a0N et\u00a0al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 79:206\u2013216","journal-title":"Ann Neurol"},{"key":"1090_CR32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","volume":"13","author":"I Kleiter","year":"2016","unstructured":"Kleiter\u00a0I, Gold\u00a0R (2016) Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 13:70\u201383","journal-title":"Neurotherapeutics"},{"key":"1090_CR33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","volume":"69","author":"I Kleiter","year":"2012","unstructured":"Kleiter\u00a0I, Hellwig\u00a0K, Berthele\u00a0A et\u00a0al (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69:239\u2013245","journal-title":"Arch Neurol"},{"key":"1090_CR34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s42451-018-0051-1","volume":"2","author":"W K\u00f6hler","year":"2019","unstructured":"K\u00f6hler\u00a0W, Bien\u00a0CG, Ehrlich\u00a0S et\u00a0al (2019) Konsensuspapier zum Einsatz der therapeutischen Apherese in der Neurologie. DGNeurologie 2:15\u201333","journal-title":"DGNeurologie"},{"key":"1090_CR35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj\u00a0AG, Hill\u00a0A, Rottinghaus\u00a0ST et al (2019) Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor\u2013experienced adult patients with PNH: the 302 study. Blood 133:540\u2013549","journal-title":"Blood"},{"key":"1090_CR36","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon\u00a0VA, Wingerchuk\u00a0DM, Kryzer\u00a0TJ et\u00a0al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"key":"1090_CR37","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458517730131","volume":"24","author":"MA Mealy","year":"2018","unstructured":"Mealy\u00a0MA, Kim\u00a0S\u2011H, Schmidt\u00a0F et al (2018) Aquaporin\u20114 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Multiple Scler\u00a0J 24:1737\u20131742","journal-title":"Multiple Scler J"},{"key":"1090_CR38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy\u00a0MA, Wingerchuk\u00a0DM, Palace\u00a0J et\u00a0al (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71:324\u2013330","journal-title":"JAMA Neurol"},{"key":"1090_CR39","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2017","unstructured":"Montcuquet\u00a0A, Collongues\u00a0N, Papeix\u00a0C et al (2017) Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Scler\u00a0J 23:1377\u20131384","journal-title":"Multiple Scler J"},{"key":"1090_CR40","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo\u00a0Z, Badihian\u00a0S, Shaygannejad\u00a0V et\u00a0al (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a\u00a0randomized clinical trial. J\u00a0Neurol 264:2003\u20132009","journal-title":"J Neurol"},{"key":"1090_CR41","volume-title":"MS Virtual 2020. 8th joint ACTRIMS-ECTRIMS meeting","author":"J Palace","year":"2020","unstructured":"Palace\u00a0J, Kleiter\u00a0I, Traboulsee\u00a0A et al (2020) Effect of satralizumab on relapse severity in neuromyelitis optica spectrum disorder (NMOSD): results from the Phase III SAkura studies. In: MS Virtual 2020. 8th joint ACTRIMS-ECTRIMS meeting"},{"key":"1090_CR42","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock\u00a0SJ, Berthele\u00a0A, Fujihara\u00a0K et al (2019) Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder. N\u00a0Engl J Med 381:614\u2013625","journal-title":"N Engl J Med"},{"key":"1090_CR43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock\u00a0SJ, Lennon\u00a0VA, Mckeon\u00a0A et al (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12:554\u2013562","journal-title":"Lancet Neurol"},{"key":"1090_CR44","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","volume":"94","author":"J Poupart","year":"2020","unstructured":"Poupart\u00a0J, Giovannelli\u00a0J, Deschamps\u00a0R et al (2020) Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology 94:e1645\u2013e1656","journal-title":"Neurology"},{"key":"1090_CR45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan\u00a0S, Mohammad\u00a0S, Tantsis\u00a0E et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J\u00a0Neurol Neurosurg Psychiatry 89:127\u2013137","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1090_CR46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","volume":"72","author":"M Ringelstein","year":"2015","unstructured":"Ringelstein\u00a0M, Ayzenberg\u00a0I, Harmel\u00a0J et al (2015) Long-term therapy with Interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 72:756\u2013763","journal-title":"JAMA Neurol"},{"key":"1090_CR47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.25805","volume":"88","author":"C Schwake","year":"2020","unstructured":"Schwake\u00a0C, Hellwig\u00a0K, Gold\u00a0R et al (2020) Reader response: comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin\u20114 antibody diseases. Ann Neurol 88:430\u2013430","journal-title":"Ann Neurol"},{"key":"1090_CR48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","volume":"88","author":"JP Stellmann","year":"2017","unstructured":"Stellmann\u00a0JP, Krumbholz\u00a0M, Friede\u00a0T et\u00a0al (2017) Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J\u00a0Neurol Neurosurg Psychiatry 88:639\u2013647","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1090_CR49","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish\u00a0H, Hellmann\u00a0MA, Mimouni\u00a0M et al (2019) Does time equal vision in the acute treatment of a\u00a0cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm 6:e572","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1090_CR50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara\u00a0M, Oeda\u00a0T, Okada\u00a0K et al (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN\u20111 study): a\u00a0multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19:298\u2013306","journal-title":"Lancet Neurol"},{"key":"1090_CR51","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","volume":"143","author":"Y Takai","year":"2020","unstructured":"Takai\u00a0Y, Misu\u00a0T, Kaneko\u00a0K et al (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 143:1431\u20131446","journal-title":"Brain"},{"key":"1090_CR52","first-page":"3","volume":"25","author":"R Tholen","year":"2019","unstructured":"Tholen\u00a0R, Dettmers\u00a0C, Henze\u00a0T et al (2019) Bewegungstherapie zur Verbesserung der Mobilit\u00e4t von Patienten mit Multipler Sklerose. Konsensusfassung f\u00fcr die S2e-Leitlinie der DGNR in Zusammenarbeit mit Physio Deutschland \u2013 Deutscher Verband f\u00fcr Physiotherapie (ZVK) e.\u202fV. Neurol Rehabil 25:3\u201340","journal-title":"Neurol Rehabil"},{"key":"1090_CR53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee\u00a0A, Greenberg\u00a0BM, Bennett\u00a0JL et al (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a\u00a0randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19:402\u2013412","journal-title":"Lancet Neurol"},{"key":"1090_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst\u00a0C, Jarius\u00a0S, Berthele\u00a0A et\u00a0al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J\u00a0Neurol 261:1\u201316","journal-title":"J Neurol"},{"key":"1090_CR55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","volume":"282","author":"S Viswanathan","year":"2015","unstructured":"Viswanathan\u00a0S, Wong\u00a0AHY, Quek\u00a0AML et\u00a0al (2015) Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J\u00a0Neuroimmunol 282:92\u201396","journal-title":"J Neuroimmunol"},{"key":"1090_CR56","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","volume":"13","author":"S Watanabe","year":"2007","unstructured":"Watanabe\u00a0S, Misu\u00a0T, Miyazawa\u00a0I et al (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a\u00a0retrospective analysis. Mult Scler 13:968\u2013974","journal-title":"Mult Scler"},{"key":"1090_CR57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk\u00a0DM, Banwell\u00a0B, Bennett\u00a0JL et\u00a0al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"1090_CR58","volume-title":"ECTRIMS","author":"DM Wingerchuk","year":"2019","unstructured":"Wingerchuk\u00a0DM, Pittock\u00a0SJ, Berthele\u00a0A et al (2019) Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder. ECTRIMS online library. Wingerchuk\u00a0D. 09\/12\/19; 279441; 142. In: ECTRIMS"},{"key":"1090_CR59","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura\u00a0T, Kleiter\u00a0I, Fujihara\u00a0K et\u00a0al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N\u00a0Engl J Med 381:2114\u20132124","journal-title":"N Engl J Med"},{"key":"1090_CR60","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458515617248","volume":"22","author":"R Yamasaki","year":"2016","unstructured":"Yamasaki\u00a0R, Matsushita\u00a0T, Fukazawa\u00a0T et\u00a0al (2016) Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Multiple Scler\u00a0J 22:1337\u20131348","journal-title":"Multiple Scler J"},{"key":"1090_CR61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000479948","volume":"24","author":"X Yang","year":"2017","unstructured":"Yang\u00a0X, Liang\u00a0J, Huang\u00a0Q et al (2017) Treatment of autoimmune glial fibrillary acidic protein astrocytopathy: follow-up in 7 cases. Neuroimmunomodulation 24:113\u2013119","journal-title":"Neuroimmunomodulation"},{"key":"1090_CR62","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","volume":"74","author":"C Zhang","year":"2017","unstructured":"Zhang\u00a0C, Tian\u00a0D\u2011C, Yang\u00a0C\u2011S et al (2017) Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol 74:1010\u20131012","journal-title":"JAMA Neurol"},{"key":"1090_CR63","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang\u00a0C, Zhang\u00a0M, Qiu\u00a0W et al (2020) Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19:391\u2013401","journal-title":"Lancet Neurol"},{"key":"1090_CR64","doi-asserted-by":"crossref","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","volume":"18","author":"AW Zuercher","year":"2019","unstructured":"Zuercher\u00a0AW, Spirig\u00a0R, Baz Morelli\u00a0A et al (2019) Next-generation Fc receptor\u2013targeting biologics for autoimmune diseases. Autoimmun Rev 18:102366","journal-title":"Autoimmun Rev"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01090-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-021-01090-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01090-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T16:08:31Z","timestamp":1617811711000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-021-01090-4"}},"subtitle":["Strategien zur Behandlung der Neuromyelitis-optica-Spektrumerkrankung und der Myelooligodendrozytenglykoprotein-Antik\u00f6rper-assoziierten Erkrankung"],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s00115-021-01090-4","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"2 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"I.\u00a0Kleiter erhielt Berater- und Vortragshonorare von Alexion, Biogen, Celgene, Chugai, Novartis, Merck, Roche sowie Forschungsunterst\u00fctzung von Diamed und Chugai Pharma. I.\u00a0Ayzenberg erhielt Berater- und Vortragshonorare von Roche Pharma, Alexion, Santhera Pharma, Merck sowie Forschungsunterst\u00fctzung von Diamed und Chugai Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}